ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Gilead Sciences and AstraZeneca side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Gilead SciencesAstraZeneca
studies on the registry7384,197
open to participants now32298
phase 3 studies under way32200
reach primary completion within a year19169
programswith a study of their own in two years32119+5 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGilead SciencesAstraZeneca
Phase 1

Gilead Sciences: 6 of its 32 programs at phase 1

  1. GS-0151phase 1
  2. GS-0415phase 1
  3. GS-1206phase 1
  4. GS-2426phase 1
  5. GS-5319phase 1

and 1 more — sign in to see them all

19%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%
Phase 2

Gilead Sciences: 6 of its 32 programs at phase 2

  1. Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 2
  2. denikitugphase 2
  3. GS-1179phase 2
  4. GS-4321phase 2
  5. PTM Cilofexor Dose Aphase 2

and 1 more — sign in to see them all

19%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%
Phase 3

Gilead Sciences: 15 of its 32 programs at phase 3

  1. anitocabtagene autoleucelphase 3
  2. domvanalimabphase 3
  3. seladelparphase 3
  4. axicabtagene ciloleucelphase 3
  5. GS-3242phase 3

and 10 more — sign in to see them all

47%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%
Approved, new studies

Gilead Sciences: 5 of its 32 programs at approved, new studies

  1. sacituzumab govitecanapproved, new study
  2. lenacapavirapproved, new study
  3. tenofovir alafenamideapproved, new study
  4. bictegravirapproved, new study
  5. Emtricitabineapproved, new study
16%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Gilead Sciences10 readouts · 2 phase 3·

Gilead Sciences, Dec ’26: 2 programs whose next study reaches primary completion

  1. anitocabtagene autoleucelphase 3 · Dec 0 · NCT05396885
  2. sacituzumab govitecanapproved, new study · Dec 0 · NCT04617522
··

Gilead Sciences, Mar ’27: 4 programs whose next study reaches primary completion

  1. domvanalimabphase 3 · Mar 0 · NCT06727565
  2. GS-0151phase 1 · Mar 0 · NCT06902519
  3. lenacapavirapproved, new study · Mar 0 · NCT06749054
  4. Optimized Background Regimen (OBR)phase 3 · Mar 0 · NCT06749054
··

Gilead Sciences, Jun ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Emtricitabineapproved, new study · Jun 0 · NCT06337032
  2. tenofovir alafenamideapproved, new study · Jun 0 · NCT06337032
·

Gilead Sciences, Aug ’27: 2 programs whose next study reaches primary completion

  1. bictegravirapproved, new study · Aug 0 · NCT07645287
  2. GS-3242phase 3 · Aug 0 · NCT07645287
··
AstraZeneca61 readouts · 16 phase 3

AstraZeneca, Nov ’26: 6 programs whose next study reaches primary completion

  1. elecoglipronphase 3 · Nov 18 · NCT07723833
  2. Elecoglipron Test formulation 1 Dose Aphase 1 · Nov 18 · NCT07723833
  3. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  4. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  5. durvalumabapproved, new study · Nov 30 · NCT07081633

and 1 more — sign in to see them all

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 7 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Gilead Sciences

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 6

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Where they overlap

Conditions where at least two of them have programs: 23 in all. A program counts in each condition its studies name most.

ConditionGilead SciencesAstraZeneca
Carcinoma, Non-Small-Cell Lungboth · compare here

Gilead Sciences in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. domvanalimabphase 3
  2. Topotecanphase 3
  3. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 18 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 13 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

Gilead Sciences in Breast Neoplasms: 4 programs

  1. amrubicinphase 3
  2. lurbinectedinphase 3
  3. trifluridine tipiracil drug combinationphase 2
  4. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Breast Neoplasms in search

AstraZeneca in Breast Neoplasms: 9 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 4 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Neoplasmsboth · compare here

Gilead Sciences in Neoplasms: 2 programs

  1. lurbinectedinphase 3
  2. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Neoplasms in search

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Lymphoma, B-Cellboth · compare here
Lymphoma, Follicularboth · compare here

Gilead Sciences in Lymphoma, Follicular: 1 program

  1. axicabtagene ciloleucelphase 3

Their studies: Gilead Sciences’ studies of Lymphoma, Follicular in search

AstraZeneca in Lymphoma, Follicular: 5 programs

  1. surovatamigphase 3
  2. camizestrantphase 3
  3. lenbelintidephase 3
  4. AZD9550phase 2
  5. AZD2389phase 2

Their studies: AstraZeneca’s studies of Lymphoma, Follicular in search

Small Cell Lung Carcinomaboth · compare here

Gilead Sciences in Small Cell Lung Carcinoma: 4 programs

  1. amrubicinphase 3
  2. lurbinectedinphase 3
  3. Topotecanphase 3
  4. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Small Cell Lung Carcinoma in search

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Squamous Cell Carcinoma of Head and Neckboth · compare here

Gilead Sciences in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. domvanalimabphase 3

Their studies: Gilead Sciences’ studies of Squamous Cell Carcinoma of Head and Neck in search

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 5 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. volrustomigphase 3
  4. monalizumabphase 3
  5. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

Triple Negative Breast Neoplasmsboth · compare here

Gilead Sciences in Triple Negative Breast Neoplasms: 1 program

  1. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Triple Negative Breast Neoplasms in search

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

Colorectal Neoplasmsboth · compare here

Gilead Sciences in Colorectal Neoplasms: 2 programs

  1. denikitugphase 2
  2. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Colorectal Neoplasms in search

AstraZeneca in Colorectal Neoplasms: 2 programs

  1. Actinium-225phase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Endometrial Neoplasmsboth · compare here

Gilead Sciences in Endometrial Neoplasms: 1 program

  1. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Endometrial Neoplasms in search

AstraZeneca in Endometrial Neoplasms: 3 programs

  1. datopotamab deruxtecanphase 3
  2. puxitatug samrotecanphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

Hyperlipidemiasboth · compare here

Gilead Sciences in Hyperlipidemias: 1 program

  1. seladelparphase 3

Their studies: Gilead Sciences’ studies of Hyperlipidemias in search

AstraZeneca in Hyperlipidemias: 3 programs

  1. laroprovstatphase 3
  2. Laroprovstat/ezetimibe FCDP-slow variantphase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hyperlipidemias in search

Multiple Myelomaboth · compare here

Gilead Sciences in Multiple Myeloma: 1 program

  1. anitocabtagene autoleucelphase 3

Their studies: Gilead Sciences’ studies of Multiple Myeloma in search

Neoplasm Metastasisboth · compare here

Gilead Sciences in Neoplasm Metastasis: 1 program

  1. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Neoplasm Metastasis in search

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Arthritis, Rheumatoidboth · compare here

Gilead Sciences in Arthritis, Rheumatoid: 1 program

  1. GS-0151phase 1

Their studies: Gilead Sciences’ studies of Arthritis, Rheumatoid in search

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Kidney Failure, Chronicboth · compare here

Gilead Sciences in Kidney Failure, Chronic: 2 programs

  1. bictegravirapproved, new study
  2. Emtricitabineapproved, new study

Their studies: Gilead Sciences’ studies of Kidney Failure, Chronic in search

AstraZeneca in Kidney Failure, Chronic: 1 program

  1. Berzanoflastphase 2

Their studies: AstraZeneca’s studies of Kidney Failure, Chronic in search

Non-alcoholic Fatty Liver Diseaseboth · compare here

Gilead Sciences in Non-alcoholic Fatty Liver Disease: 2 programs

  1. seladelparphase 3
  2. cilofexorphase 3

Their studies: Gilead Sciences’ studies of Non-alcoholic Fatty Liver Disease in search

AstraZeneca in Non-alcoholic Fatty Liver Disease: 1 program

  1. AZD9550phase 2

Their studies: AstraZeneca’s studies of Non-alcoholic Fatty Liver Disease in search

Ovarian Neoplasmsboth · compare here

Gilead Sciences in Ovarian Neoplasms: 1 program

  1. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Ovarian Neoplasms in search

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

COVID-19both · compare here

Gilead Sciences in COVID-19: 1 program

  1. obeldesivirphase 3

Their studies: Gilead Sciences’ studies of COVID-19 in search

AstraZeneca in COVID-19: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of COVID-19 in search

Kidney Diseasesboth · compare here

Gilead Sciences in Kidney Diseases: 1 program

  1. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Kidney Diseases in search

AstraZeneca in Kidney Diseases: 1 program

  1. zibotentanphase 3

Their studies: AstraZeneca’s studies of Kidney Diseases in search

Lung Neoplasmsboth · compare here

Gilead Sciences in Lung Neoplasms: 1 program

  1. amrubicinphase 3

Their studies: Gilead Sciences’ studies of Lung Neoplasms in search

AstraZeneca in Lung Neoplasms: 1 program

  1. osimertinibapproved, new study

Their studies: AstraZeneca’s studies of Lung Neoplasms in search

Lupus Nephritisboth · compare here

Gilead Sciences in Lupus Nephritis: 1 program

  1. Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 2

Their studies: Gilead Sciences’ studies of Lupus Nephritis in search

AstraZeneca in Lupus Nephritis: 1 program

  1. anifrolumabapproved, new study

Their studies: AstraZeneca’s studies of Lupus Nephritis in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Gilead Sciences in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. axicabtagene ciloleucelphase 3

Their studies: Gilead Sciences’ studies of Lymphoma, Large B-Cell, Diffuse in search

AstraZeneca in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Large B-Cell, Diffuse in search

Respiratory Syncytial Virus Infectionsboth · compare here

Gilead Sciences in Respiratory Syncytial Virus Infections: 1 program

  1. obeldesivirphase 3

Their studies: Gilead Sciences’ studies of Respiratory Syncytial Virus Infections in search

AstraZeneca in Respiratory Syncytial Virus Infections: 1 program

  1. Palivizumabapproved, new study

Their studies: AstraZeneca’s studies of Respiratory Syncytial Virus Infections in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Gilead Sciences 16 of 32 · AstraZeneca 68 of 119 programs (40 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).